| scholarly article | Q13442814 |
| P2093 | author name string | Alberto Fulvi | |
| Bruno Gori | |||
| Ester Del Signore | |||
| Filippo de Marinis | |||
| Serena Ricciardi | |||
| Salvatore Intagliata | |||
| P2860 | cites work | Randomized, placebo-controlled phase II study of vandetanib plus docetaxel in previously treated non small-cell lung cancer | Q42631933 |
| A multicenter phase II study of erlotinib and sorafenib in chemotherapy-naive patients with advanced non-small cell lung cancer | Q43098017 | ||
| Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancer. | Q43138109 | ||
| Sunitinib in combination with gemcitabine plus cisplatin for advanced non-small cell lung cancer: a phase I dose-escalation study | Q43147962 | ||
| Phase II, multicenter, uncontrolled trial of single-agent sorafenib in patients with relapsed or refractory, advanced non-small-cell lung cancer | Q43299264 | ||
| Novel 4-anilinoquinazolines with C-7 basic side chains: design and structure activity relationship of a series of potent, orally active, VEGF receptor tyrosine kinase inhibitors | Q43907793 | ||
| ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. | Q44106085 | ||
| Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lun | Q45309210 | ||
| Efficacy and safety of axitinib in patients with advanced non-small-cell lung cancer: results from a phase II study. | Q45930096 | ||
| Phase I trial of pazopanib in patients with advanced cancer. | Q45976168 | ||
| Vandetanib versus gefitinib in patients with advanced non-small-cell lung cancer: results from a two-part, double-blind, randomized phase ii study | Q46068556 | ||
| Clinical evaluation of ZD6474, an orally active inhibitor of VEGF and EGF receptor signaling, in patients with solid, malignant tumors | Q46499714 | ||
| The tyrosine kinase inhibitor cediranib blocks ligand-induced vascular endothelial growth factor receptor-3 activity and lymphangiogenesis | Q46535751 | ||
| A phase II double-blind study to investigate efficacy and safety of two doses of the triple angiokinase inhibitor BIBF 1120 in patients with relapsed advanced non-small-cell lung cancer. | Q54621891 | ||
| Vandetanib Versus placebo in patients with advanced non-small-cell lung cancer after prior therapy with an epidermal growth factor receptor tyrosine kinase inhibitor: a randomized, double-blind phase III trial (ZEPHYR) | Q83523403 | ||
| ??? | Q28304346 | ||
| BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy | Q27650860 | ||
| Angiogenesis in cancer and other diseases | Q27861015 | ||
| New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) | Q28131668 | ||
| AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer | Q28251373 | ||
| Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results | Q28262507 | ||
| R Regulation of tumor angiogenesis and metastasis by FGF and PDGF signaling pathways | Q28275289 | ||
| BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis | Q29617585 | ||
| Angiogenesis as a therapeutic target | Q29619525 | ||
| Angiogenic factors | Q29620582 | ||
| Multicenter, phase II trial of sunitinib in previously treated, advanced non-small-cell lung cancer | Q30422736 | ||
| Sunitinib in combination with docetaxel in patients with advanced solid tumors: a phase I dose-escalation study | Q33996608 | ||
| Phase 1b study of motesanib, an oral angiogenesis inhibitor, in combination with carboplatin/paclitaxel and/or panitumumab for the treatment of advanced non-small cell lung cancer | Q34089521 | ||
| ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases. | Q34166741 | ||
| AMG 706, an oral, multikinase inhibitor that selectively targets vascular endothelial growth factor, platelet-derived growth factor, and kit receptors, potently inhibits angiogenesis and induces regression in tumor xenografts | Q34563207 | ||
| Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial | Q35576189 | ||
| Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis | Q36111400 | ||
| Inhibition of angiogenesis in the treatment of non-small cell lung cancer | Q36950548 | ||
| Fibroblast growth factor regulation of neovascularization | Q37129668 | ||
| Phase I and pharmacokinetic study of daily oral AZD2171, an inhibitor of vascular endothelial growth factor tyrosine kinases, in combination with carboplatin and paclitaxel in patients with advanced non-small-cell lung cancer: the National Cancer In | Q37132598 | ||
| Axitinib, a novel anti-angiogenic drug with promising activity in various solid tumors. | Q37179139 | ||
| VEGFs and receptors involved in angiogenesis versus lymphangiogenesis | Q37397202 | ||
| Phase II study of continuous daily sunitinib dosing in patients with previously treated advanced non-small cell lung cancer | Q37424049 | ||
| Randomized, double-blind trial of carboplatin and paclitaxel with either daily oral cediranib or placebo in advanced non-small-cell lung cancer: NCIC clinical trials group BR24 study | Q37633813 | ||
| Axitinib (AG-013736). | Q37674170 | ||
| Pazopanib: Clinical development of a potent anti-angiogenic drug | Q37748042 | ||
| Phase I and pharmacokinetic study of sorafenib, an oral multikinase inhibitor, in Japanese patients with advanced refractory solid tumors | Q40092301 | ||
| Sorafenib is efficacious and tolerated in combination with cytotoxic or cytostatic agents in preclinical models of human non-small cell lung carcinoma | Q40275475 | ||
| Synergistic antitumor effects of combined epidermal growth factor receptor and vascular endothelial growth factor receptor-2 targeted therapy | Q40293653 | ||
| P275 | copyright license | Creative Commons Attribution-NonCommercial 3.0 Unported | Q18810331 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P304 | page(s) | 429-440 | |
| P577 | publication date | 2011-11-17 | |
| P1433 | published in | Therapeutics and Clinical Risk Management | Q15766913 |
| P1476 | title | New antiangiogenics in non-small cell lung cancer treatment: Vargatef™ (BIBF 1120) and beyond | |
| P478 | volume | 7 |
| Q36996220 | Customised, Individualised Treatment of Metastatic Non-Small-Cell Lung Carcinoma (NSCLC) |
| Q38430583 | Nintedanib: A Review of Its Use as Second-Line Treatment in Adults with Advanced Non-Small Cell Lung Cancer of Adenocarcinoma Histology |
| Q39839324 | Pharmacokinetic Properties of Nintedanib in Healthy Volunteers and Patients With Advanced Cancer |
| Q36957621 | Reducing lung function decline in patients with idiopathic pulmonary fibrosis: potential of nintedanib |
Search more.